Early virological failure with a combination of tenofovir, didanosine and efavirenz

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 171-177

  Podzamczer, Daniel ^a   Ferrer, Elena ^a   Gatell, Josep Maria ^b   Niubo, Jordi ^a   Dalmau, David ^c   Leon, Agathe ^b   Knobel, Hernando ^d   Polo, Carolina ^a   Iniguez, Daniel ^a   Ruiz, Isaac ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LOPINAVIR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; OXAZINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS LOAD; ANTIBIOTIC RESISTANCE; BLOOD; DRUG EFFECT; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; TIME; VIREMIA; VIROLOGY;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; OXAZINES; PHOSPHONIC ACIDS; PYRIMIDINONES; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; VIREMIA;

EID: 20044366980     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamividine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865-1873.
2. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocana I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez-Lacasa J, Miro, JM, Badia X, Casado A, Lupo S, Cahn P, Manos M, Estela J & the Combine Study Team. A randomized clinical trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naive patients (The Combine Study). Antiviral Therapy 2002; 7:81-90.
3. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J & Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
4. O'Brien PC & Fleming TH. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
5. Farthing C, Kanlouh H & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. 2nd IAS Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract 43.
6. Jemsek J, Hutcherson P & Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 51.
7. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, Coakley DF, Lu B, Toole JJ & Cheng AK for the 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. Journal of the American Medical Association 2004; 292:191-201.
8. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW & Rousseau F for the FTC-301A Study Team. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients. A randomized trial. Journal of the American Medical Association 2004; 292:180-190.
9. Pulido F, Arribas, JR, Miro JM, Costa MA, Gonzalez J, Rubio R, Pena JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vazquez JJ & Gatell JM for the EfaVIP Cohort Study Group. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study). Journal of Acquired Immune Deficiency Syndromes 2004; 35:343-350.
10. Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Puig J, Paredes R, Ruiz L, Pruvost A, Grassi J & Clotet B. Unexpected CD4 cell-count decline in patients receiving didanosine- and tenofovir-based regimens despite undetectable viral load. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 749.
11. Barrios A, Negredo E, Vilaró-Rodríguez J, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Terron J, Casas E, Riera M, Vergara A, Gonzalez-Lahoz J, Soriano V & ddI+TDF+EFV Spanish Study Group. Safety and efficacy of a QD simplification regimen. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 566.
12. Blanchard JN, Wohlfeiler M, Canas A, King K & Tyler Lonergan J. Pancreatitis treated with didanosine and tenofovir disoproxil fumarate. Clinical Infectious Diseases 2003; 37:e57-62.
13. Ray AS, Olson L & Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrobial Agents & Chemotherapy 2004; 48:1089-1095.
14. Pecora Fulco P & Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Annals of Pharmacotherapy 2003; 37:1325-1328.
15. Kaul S, Damle B, Bassi K, Xie J, Gale J, Ryan K & Hanna G. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules (ddI-EC) in combination with tenofovir disoproxil fumarate (TDF) and food for a once-daily antiretroviral regimen. 4th International Workshop on Clinical Pharmacology of HIV Therapy. 27-29 March 2003, Cannes, France. Abstract 8.1.
16. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein A & Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 1994; 121:263-268.
17. Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JMA, Pennington KN & St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. Journal of Virology 1996; 70:5922-5929.
18. McColl DJ, Parkin NT & Miller MD. Characterization of patient-derived HIV-1 isolates containing the L74V or K65R mutations in reverse transcriptase (RT). 44th Interscience Conference on Antimicrobial Agents & Chemotherapy. 30 October-2 November 2004, Washington DC, USA. Abstract H-178.
19. Boyer PL, Gao HK & Hughes SH. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrobial Agents & Chemotherapy 1998; 42:447-452.
20. Huang W, Gamarnik A, Limoli K, Petropoulos CJ & Whitcomb JM. Amino acid substitution at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. Journal of Virology 2003; 77:1512-1523.
21. 3 receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomised comparative trial. 44th Interscience Conference on Antimicrobial Agents & Chemotherapy. 30 October-2 November 2004, Washington DC, USA. Abstract H-566.
22. Leon A, Martínez E, Mallolas J, Laguno M, Blanco JL, Pumarola T & Gatell JM. Early virological failure associated with selection of resistance mutations in treatment naive HIV-infected adults receiving efavirenz or nevirapine plus didanosine and tenofovir. AIDS [research letter] (in press).